Kurt Hertogs

5.5k total citations
84 papers, 4.3k citations indexed

About

Kurt Hertogs is a scholar working on Infectious Diseases, Virology and Hepatology. According to data from OpenAlex, Kurt Hertogs has authored 84 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Infectious Diseases, 70 papers in Virology and 12 papers in Hepatology. Recurrent topics in Kurt Hertogs's work include HIV Research and Treatment (70 papers), HIV/AIDS drug development and treatment (70 papers) and HIV/AIDS Research and Interventions (43 papers). Kurt Hertogs is often cited by papers focused on HIV Research and Treatment (70 papers), HIV/AIDS drug development and treatment (70 papers) and HIV/AIDS Research and Interventions (43 papers). Kurt Hertogs collaborates with scholars based in United States, Germany and Belgium. Kurt Hertogs's co-authors include Brendan Larder, Stuart Bloor, Veronica Miller, Schlomo Staszewski, Rudi Pauwels, Sharon D. Kemp, Marie‐Pierre de Béthune, Christel Van den Eynde, Margriet Van Houtte and Martin Stürmer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Annals of Internal Medicine and Hepatology.

In The Last Decade

Kurt Hertogs

84 papers receiving 4.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kurt Hertogs United States	40	3.7k	3.5k	568	554	275	84	4.3k
Christian Callebaut United States	29	1.7k 0.5×	1.5k 0.4×	544 1.0×	525 0.9×	225 0.8×	96	2.8k
Ricardo Sobhie Diaz Brazil	30	2.0k 0.5×	1.9k 0.5×	346 0.6×	672 1.2×	308 1.1×	159	3.1k
Deborah A. Paul United States	17	1.5k 0.4×	1.6k 0.5×	433 0.8×	516 0.9×	264 1.0×	22	2.3k
L Rimsky United States	25	2.0k 0.5×	1.9k 0.5×	692 1.2×	462 0.8×	189 0.7×	39	3.2k
Maureen Oliveira Canada	31	2.8k 0.7×	2.6k 0.7×	658 1.2×	509 0.9×	133 0.5×	95	3.2k
J C Quintero United States	13	1.7k 0.5×	1.6k 0.4×	529 0.9×	280 0.5×	150 0.5×	19	2.3k
Patricia Barditch‐Crovo United States	17	1.7k 0.5×	2.0k 0.6×	320 0.6×	635 1.1×	131 0.5×	27	3.0k
Jeannette M. Whitcomb United States	32	3.4k 0.9×	3.7k 1.0×	1.1k 1.9×	758 1.4×	256 0.9×	57	4.8k
Jon H. Condra United States	27	3.4k 0.9×	3.2k 0.9×	1.1k 1.9×	1.0k 1.9×	275 1.0×	47	5.1k
Rose V. Thomas United States	17	1.3k 0.4×	1.1k 0.3×	478 0.8×	567 1.0×	83 0.3×	20	2.2k

Countries citing papers authored by Kurt Hertogs

Since Specialization

Citations

This map shows the geographic impact of Kurt Hertogs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kurt Hertogs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kurt Hertogs more than expected).

Fields of papers citing papers by Kurt Hertogs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kurt Hertogs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kurt Hertogs. The network helps show where Kurt Hertogs may publish in the future.

Co-authorship network of co-authors of Kurt Hertogs

This figure shows the co-authorship network connecting the top 25 collaborators of Kurt Hertogs. A scholar is included among the top collaborators of Kurt Hertogs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kurt Hertogs. Kurt Hertogs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Goethals, Olivia, Ann Vos, Marcia Van Ginderen, et al.. (2010). Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology. 402(2). 338–346. 51 indexed citations

2.

Jochmans, Dirk, Jérôme Deval, Bart Kesteleyn, et al.. (2006). Indolopyridones Inhibit Human Immunodeficiency Virus Reverse Transcriptase with a Novel Mechanism of Action. Journal of Virology. 80(24). 12283–12292. 77 indexed citations

3.

Stürmer, Martin, Schlomo Staszewski, Hans Wilhelm Doerr, & Kurt Hertogs. (2003). A 6-Base Pair Insertion in the Protease Gene of HIV Type 1 Detected in a Protease Inhibitor-Naive Patient Is Not Associated with Indinavir Treatment Failure. AIDS Research and Human Retroviruses. 19(11). 967–968. 11 indexed citations

4.

DiRienzo, A. Gregory, Victor DeGruttola, Brendan Larder, & Kurt Hertogs. (2003). Non‐parametric methods to predict HIV drug susceptibility phenotype from genotype. Statistics in Medicine. 22(17). 2785–2798. 27 indexed citations

5.

Adjé-Touré, Christiane, Debra L. Hanson, Thierry H. Roels, et al.. (2003). Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS–Drug Access Initiative in Abidjan, Côte dʼIvoire. AIDS. 17. S23–S29. 14 indexed citations

6.

Casado, José L., Santiago Moreno, Kurt Hertogs, et al.. (2002). Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. AIDS. 16(1). 47–52. 20 indexed citations

7.

Casado, José L., Ana Moreno, Kurt Hertogs, Fernando Dronda, & Santiago Moreno. (2002). Extent and Importance of Cross-Resistance to Efavirenz after Nevirapine Failure. AIDS Research and Human Retroviruses. 18(11). 771–775. 17 indexed citations

8.

Montavon, Céline, Coumba Touré‐Kâne, John N. Nkengasong, et al.. (2002). CRF06-cpx: A New Circulating Recombinant Form of HIV-1 in West Africa Involving Subtypes A, G, K, and J. JAIDS Journal of Acquired Immune Deficiency Syndromes. 29(5). 522–530. 3 indexed citations

9.

Casado, José L., Fernando Dronda, Kurt Hertogs, et al.. (2001). Efficacy, Tolerance, and Pharmacokinetics of the Combination of Stavudine, Nevirapine, Nelfinavir, and Saquinavir as Salvage Regimen after Ritonavir or Indinavir Failure. AIDS Research and Human Retroviruses. 17(2). 93–98. 12 indexed citations

10.

Ross, Lisa, Qiming Liao, Haitao Gao, et al.. (2001). Impact of HIV Type 1 Drug Resistance Mutations and Phenotypic Resistance Profile on Virologic Response to Salvage Therapy. AIDS Research and Human Retroviruses. 17(15). 1379–1385. 12 indexed citations

11.

Dronda, Fernando, José L. Casado, Santiago Moreno, et al.. (2001). Phenotypic Cross-Resistance to Nelfinavir: The Role of Prior Antiretroviral Therapy and the Number of Mutations in the Protease Gene. AIDS Research and Human Retroviruses. 17(3). 211–215. 18 indexed citations

12.

Cheingsong, Rachanee, Thierry H. Roels, Chantal Maurice, et al.. (2001). High Prevalence of Genotypic and Phenotypic HIV-1 Drug-Resistant Strains Among Patients Receiving Antiretroviral Therapy in Abidjan, Côte d'Ivoire. JAIDS Journal of Acquired Immune Deficiency Syndromes. 26(5). 501–506. 33 indexed citations

13.

Vandamme, Anne–Mieke, François Houÿez, Dénes Bánhegyi, et al.. (2001). Laboratory Guidelines for the Practical Use of HIV Drug Resistance Tests in Patient Follow-Up. Antiviral Therapy. 6(1). 21–39. 56 indexed citations

14.

Cheingsong, Rachanee, Thierry H. Roels, Chantal Maurice, et al.. (2001). High Prevalence of Genotypic and Phenotypic HIV-1 Drug-Resistant Strains Among Patients Receiving Antiretroviral Therapy in Abidjan, Côte d'Ivoire. JAIDS Journal of Acquired Immune Deficiency Syndromes. 26(5). 501–506. 82 indexed citations

15.

Weidle, Paul J., Cissy Kityo, Peter Mugyenyi, et al.. (2001). Resistance to Antiretroviral Therapy Among Patients in Uganda. JAIDS Journal of Acquired Immune Deficiency Syndromes. 26(5). 495–500. 16 indexed citations

16.

Dybul, Mark, Tae‐Wook Chun, Christian Yoder, et al.. (2001). Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters. Proceedings of the National Academy of Sciences. 98(26). 15161–15166. 111 indexed citations

17.

Wegner, Scott A., Stephanie K. Brodine, John R. Mascola, et al.. (2000). Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel. AIDS. 14(8). 1009–1015. 101 indexed citations

18.

Cozzi‐Lepri, Alessandro, Caroline Sabin, Schlomo Staszewski, et al.. (2000). Resistance Profiles in Patients with Viral Rebound on Potent Antiretroviral Therapy. The Journal of Infectious Diseases. 181(3). 1143–1147. 37 indexed citations

19.

Miller, Veronica, Andrew Phillips, Schlomo Staszewski, et al.. (1998). Dual Resistance to Zidovudine and Lamivudine in Patients Treated with Zidovudine‐Lamivudine Combination Therapy: Association with Therapy Failure. The Journal of Infectious Diseases. 177(6). 1521–1532. 74 indexed citations

20.

Leenders, William P. J., et al.. (1994). Hepatitis δ virus attaches to human hepatocytes via human liver endonexin II, a specific HBsAg binding protein. Journal of Viral Hepatitis. 1(1). 33–38. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact